BIAFW — bioAffinity Technologies, Inc.
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 1712762 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 1,070,280 | -43,896 | -3,510,672 | -5,277,023 | 7,553,671 | 2,550,034 | 3,639,110 |
| Jun 2026 | 1,510,579 | 422,742 | -3,334,864 | -3,366,082 | 7,619,279 | 2,429,719 | 3,850,482 |
| Mar 2026 | 1,351,527 | 422,891 | -3,616,976 | -3,630,610 | 7,945,252 | 3,098,366 | 4,283,866 |
| Dec 2025 | 1,538,813 | 638,687 | -3,190,963 | -3,137,466 | 10,960,772 | 6,449,782 | 3,683,116 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-11,468,205
Investing CF
$-91,988
Financing CF
$13,187,077
CapEx
$-109,061
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-75,550,756
Inventory
$82,378
Receivables
$894,823
ST Investments
—
EBIT TTM
$-15,134,042
Pretax Income TTM
$-15,178,879
Interest Exp TTM
$44,837
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$5,900,985
EBITDA
$-11,968,556
Free Cash Flow
$-6,909,285
Enterprise Value
—
Total Cash
$2,429,719
Total Debt
$1,435,005
Shares Out
—
Trailing EPS
—
Book Value
$24.29
ROE
-1860.2%
ROA
-125.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 6,107,959 | -10,626,508 | -14,909,754 | 10,960,772 | 3,683,116 | 7,277,656 | -9,328,842 |
| Dec 2024 | 9,362,022 | -8,953,445 | -9,039,831 | 6,513,667 | 3,911,631 | 2,602,036 | -7,264,795 |
| Dec 2023 | 2,532,499 | -7,973,228 | -7,937,011 | 8,221,552 | 3,366,297 | 4,855,255 | -6,037,806 |
| Dec 2022 | 4,803 | -4,011,058 | -8,154,113 | 12,182,125 | 1,138,682 | 11,043,443 | -4,070,845 |
TTM Snapshot
Revenues TTM
$5,900,985
NetIncome TTM
$-15,185,242
OpCashFlow TTM
—
Assets (Latest)
$7,619,279
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IDXX | IDEXX LABORATORIES INC /DE | $54.38B | $690.24 | — |
| IQV | IQVIA HOLDINGS INC. | $42.45B | $257.60 | — |
| INCY | INCYTE CORP | $24.27B | $119.09 | — |
| MEDP | Medpace Holdings, Inc. | $18.27B | $653.09 | — |
| CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | $15.92B | $332.16 | — |
News headlines (Yahoo Finance, 1h cache)
BIAF Stock Dips Post Q3 Earnings Despite Rising Test Demand, Sales Down
2026-11-13 15:22 · Yahoo
bioAffinity Technologies CEO: Record CyPath Lung testing fuels growth ambitions
2026-11-11 18:35 · Yahoo
bioAffinity Technologies posts record monthly volume for CyPath Lung test
2026-11-11 15:02 · Yahoo
bioAffinity posts record month for CyPath Lung cancer test
2026-11-11 13:37 · Yahoo
bioAffinity Technologies Reports Record Monthly Testing Volume in October for Its Noninvasive CyPath® Lung Test
2026-11-11 13:00 · Yahoo
bioAffinity Technologies Reports Third Quarter 2026 Results and Continued Momentum in CyPath® Lung Commercialization
2026-11-06 22:40 · Yahoo
bioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness Month
2026-10-29 12:00 · Yahoo
bioAffinity Technologies expands Lung diagnostics pipeline into COPD and Asthma
2026-10-27 15:17 · Yahoo
bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026
2026-10-15 12:00 · Yahoo
bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026
2026-10-13 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.